AP652A - Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. - Google Patents
Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. Download PDFInfo
- Publication number
- AP652A AP652A APAP/P/1997/001089A AP9701089A AP652A AP 652 A AP652 A AP 652A AP 9701089 A AP9701089 A AP 9701089A AP 652 A AP652 A AP 652A
- Authority
- AP
- ARIPO
- Prior art keywords
- cis
- amino
- zidovudine
- pyrimidin
- purin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9506490.3A GB9506490D0 (en) | 1995-03-30 | 1995-03-30 | Antiviral combinations |
GBGB9506489.5A GB9506489D0 (en) | 1995-03-30 | 1995-03-30 | Antiviral combinations |
PCT/EP1996/001352 WO1996030025A1 (en) | 1995-03-30 | 1996-03-28 | Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9701089A0 AP9701089A0 (en) | 1997-10-31 |
AP652A true AP652A (en) | 1998-06-19 |
Family
ID=26306774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1997/001089A AP652A (en) | 1995-03-30 | 1996-03-28 | Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. |
Country Status (36)
Country | Link |
---|---|
US (1) | US6417191B1 (hu) |
EP (1) | EP0817637B1 (hu) |
JP (1) | JP2954357B2 (hu) |
KR (1) | KR100542536B1 (hu) |
CN (1) | CN1103593C (hu) |
AP (1) | AP652A (hu) |
AT (1) | ATE220551T1 (hu) |
AU (1) | AU715213B2 (hu) |
BR (3) | BRPI9612992B1 (hu) |
CA (1) | CA2216634C (hu) |
CZ (1) | CZ295940B6 (hu) |
DE (3) | DE122005000029I1 (hu) |
DK (1) | DK0817637T3 (hu) |
EA (1) | EA000626B3 (hu) |
EE (1) | EE04047B1 (hu) |
ES (1) | ES2179193T3 (hu) |
FR (1) | FR05C0022I2 (hu) |
GE (1) | GEP20022647B (hu) |
HK (1) | HK1009401A1 (hu) |
HU (1) | HU224010B1 (hu) |
IL (1) | IL117727A (hu) |
LU (1) | LU91171I2 (hu) |
MX (1) | MX9707316A (hu) |
MY (1) | MY115461A (hu) |
NL (1) | NL300195I2 (hu) |
NO (2) | NO313787B1 (hu) |
NZ (1) | NZ306419A (hu) |
OA (1) | OA10616A (hu) |
PL (1) | PL187085B1 (hu) |
PT (1) | PT817637E (hu) |
RO (1) | RO117995B1 (hu) |
SI (1) | SI0817637T1 (hu) |
SK (1) | SK283825B6 (hu) |
TR (1) | TR199701074T1 (hu) |
UA (1) | UA60293C2 (hu) |
WO (1) | WO1996030025A1 (hu) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544961B1 (en) * | 1996-06-25 | 2003-04-08 | Smithkline Beecham Corporation | Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV |
US6113920A (en) * | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
PE74799A1 (es) * | 1997-05-17 | 1999-08-13 | Glaxo Group Ltd | Combinaciones antivirales |
AU769660B2 (en) * | 1997-05-17 | 2004-01-29 | Glaxo Group Limited | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
GB9709945D0 (en) * | 1997-05-17 | 1997-07-09 | Glaxo Group Ltd | A novel salt |
GB9809213D0 (en) * | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
WO1999060988A2 (en) * | 1998-05-29 | 1999-12-02 | University Of Florida | Combination therapy for treatment of fiv infection |
US6875773B1 (en) | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
US6432966B2 (en) | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
AP2220A (en) * | 2001-05-11 | 2011-03-24 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
TW200403061A (en) * | 2002-06-04 | 2004-03-01 | Glaxo Group Ltd | Pharmaceutical compositions |
US20040224916A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
JP4485520B2 (ja) | 2003-03-24 | 2010-06-23 | エフ.ホフマン−ラ ロシュ アーゲー | 逆転写酵素阻害剤としてのベンジル−ピリダジノン類 |
WO2005040816A1 (en) | 2003-10-24 | 2005-05-06 | Immunaid Pty Ltd | Method of therapy |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
ES2550152T3 (es) | 2006-12-13 | 2015-11-04 | F. Hoffmann-La Roche Ag | Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa |
AU2008213744B2 (en) * | 2007-02-09 | 2013-12-05 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
DK2435825T3 (en) | 2009-05-27 | 2015-10-19 | Biotempus Ltd | Modes for medical care |
NZ627826A (en) | 2010-01-27 | 2016-01-29 | Viiv Healthcare Co | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide |
MX2016002560A (es) | 2013-08-29 | 2016-10-26 | Teva Pharma | Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir. |
AU2015245217A1 (en) | 2014-04-08 | 2016-10-13 | Teva Pharmaceutical Industries Ltd. | Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir |
WO2016023082A1 (en) | 2014-08-12 | 2016-02-18 | Monash University | Lymph directing prodrugs |
CN118063537A (zh) | 2015-09-08 | 2024-05-24 | 莫纳什大学 | 定向淋巴的前药 |
EP3675838A4 (en) * | 2017-08-29 | 2021-04-21 | PureTech LYT, Inc. | LIPID PRODUCTS DIRECTED TO THE LYMPHATIC SYSTEM |
US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
IL295362A (en) | 2020-02-05 | 2022-10-01 | Puretech Lyt Inc | Lipid drug inhibitors of neurosteroids |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015309A1 (en) * | 1991-03-06 | 1992-09-17 | The Wellcome Foundation Limited | Antiviral nucleoside combination |
EP0513917A1 (en) * | 1991-05-16 | 1992-11-19 | Glaxo Group Limited | Antiviral combinations containing nucleoside analogs |
WO1993023021A2 (en) * | 1992-05-13 | 1993-11-25 | The Wellcome Foundation Limited | Therapeutic combinations |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5122517A (en) | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
GB9417249D0 (en) | 1994-08-26 | 1994-10-19 | Wellcome Found | A novel salt |
US5869461A (en) | 1995-03-16 | 1999-02-09 | Yale University | Reducing toxicity of L-nucleosides with D-nucleosides |
US6544961B1 (en) | 1996-06-25 | 2003-04-08 | Smithkline Beecham Corporation | Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV |
HUP9903098A3 (en) | 1996-06-25 | 2000-01-28 | Glaxo Group Ltd | Combination comprising vx478, zidovudine and/or 1592u89 and pharmaceutical composition containing them |
DE10226522A1 (de) * | 2002-06-14 | 2003-12-24 | Degussa | Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung |
-
1996
- 1996-03-27 MY MYPI96001152A patent/MY115461A/en unknown
- 1996-03-28 BR BRPI9612992-1A patent/BRPI9612992B1/pt not_active IP Right Cessation
- 1996-03-28 PL PL96322532A patent/PL187085B1/pl unknown
- 1996-03-28 AP APAP/P/1997/001089A patent/AP652A/en active
- 1996-03-28 EP EP96911953A patent/EP0817637B1/en not_active Expired - Lifetime
- 1996-03-28 CZ CZ19973090A patent/CZ295940B6/cs not_active IP Right Cessation
- 1996-03-28 KR KR1019970706824A patent/KR100542536B1/ko not_active IP Right Cessation
- 1996-03-28 PT PT96911953T patent/PT817637E/pt unknown
- 1996-03-28 BR BRPI9607851A patent/BRPI9607851B8/pt unknown
- 1996-03-28 TR TR97/01074T patent/TR199701074T1/xx unknown
- 1996-03-28 JP JP8528931A patent/JP2954357B2/ja not_active Expired - Lifetime
- 1996-03-28 HU HU9801571A patent/HU224010B1/hu active Protection Beyond IP Right Term
- 1996-03-28 ES ES96911953T patent/ES2179193T3/es not_active Expired - Lifetime
- 1996-03-28 RO RO97-01795A patent/RO117995B1/ro unknown
- 1996-03-28 GE GEAP19963898A patent/GEP20022647B/en unknown
- 1996-03-28 US US08/930,225 patent/US6417191B1/en not_active Expired - Lifetime
- 1996-03-28 SK SK1295-97A patent/SK283825B6/sk not_active IP Right Cessation
- 1996-03-28 MX MX9707316A patent/MX9707316A/es active IP Right Grant
- 1996-03-28 DE DE200512000029 patent/DE122005000029I1/de active Pending
- 1996-03-28 AU AU54972/96A patent/AU715213B2/en not_active Expired
- 1996-03-28 DK DK96911953T patent/DK0817637T3/da active
- 1996-03-28 AT AT96911953T patent/ATE220551T1/de active
- 1996-03-28 EA EA199700203A patent/EA000626B3/ru not_active IP Right Cessation
- 1996-03-28 WO PCT/EP1996/001352 patent/WO1996030025A1/en active IP Right Grant
- 1996-03-28 SI SI9630494T patent/SI0817637T1/xx unknown
- 1996-03-28 CA CA002216634A patent/CA2216634C/en not_active Expired - Lifetime
- 1996-03-28 CN CN96194050A patent/CN1103593C/zh not_active Expired - Lifetime
- 1996-03-28 UA UA97094740A patent/UA60293C2/uk unknown
- 1996-03-28 NZ NZ306419A patent/NZ306419A/xx not_active IP Right Cessation
- 1996-03-28 EE EE9700240A patent/EE04047B1/xx not_active IP Right Cessation
- 1996-03-28 BR BRPI9607851-0A patent/BR9607851B1/pt active IP Right Grant
- 1996-03-28 DE DE1996622386 patent/DE122005000029I2/de active Active
- 1996-03-28 DE DE69622386T patent/DE69622386T2/de not_active Expired - Lifetime
- 1996-03-29 IL IL11772796A patent/IL117727A/xx not_active IP Right Cessation
-
1997
- 1997-09-17 OA OA70075A patent/OA10616A/en unknown
- 1997-09-29 NO NO19974510A patent/NO313787B1/no not_active IP Right Cessation
-
1998
- 1998-09-04 HK HK98110458A patent/HK1009401A1/xx not_active IP Right Cessation
-
2005
- 2005-05-04 LU LU91171C patent/LU91171I2/fr unknown
- 2005-05-09 FR FR05C0022C patent/FR05C0022I2/fr active Active
- 2005-05-09 NL NL300195C patent/NL300195I2/nl unknown
- 2005-05-24 NO NO2005014C patent/NO2005014I2/no unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015309A1 (en) * | 1991-03-06 | 1992-09-17 | The Wellcome Foundation Limited | Antiviral nucleoside combination |
EP0513917A1 (en) * | 1991-05-16 | 1992-11-19 | Glaxo Group Limited | Antiviral combinations containing nucleoside analogs |
WO1993023021A2 (en) * | 1992-05-13 | 1993-11-25 | The Wellcome Foundation Limited | Therapeutic combinations |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP652A (en) | Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. | |
AU727983B2 (en) | Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV | |
EP1113802B1 (en) | Antiviral combinations of lamivudine and adefovir | |
US6486136B1 (en) | Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV | |
US6432966B2 (en) | Antiviral combinations | |
WO2000016779A1 (en) | Antiviral combinations comprising lamivudine and abacavir | |
WO2000018383A2 (en) | Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester | |
AU8017298A (en) | Antiviral combinations containing the carbocyclic nucleoside 1592u89 | |
MXPA98010386A (en) | Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of |